CoChat

Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

Open access
Pittock, Sean J., Barnett, Michael, Bennett, Jeffrey L., Berthele, Achim, de Sèze, Jérôme, Levy, Michael, Nakashima, Ichiro, Oreja‐Guevara, Celia, Palace, Jacqueline, Paul, Friedemann, Pozzilli, Carlo, Yountz, Marcus, Allen, Kerstin, Mashhoon, Yasmin, Kim, Ho Jin · 2023 · Annals of Neurology
Cited by 212

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Objective: CHAMPION‐NMOSD (NCT04201262) is a phase 3, open‐label, externally controlled interventional study evaluating the efficacy and safety of the terminal complement inhibitor ravulizumab in adult patients with anti–aquaporin‐4 antibody–positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab binds the same complement component 5 epitope as the approved therapeutic eculizumab but has a longer half‐life, enabling an extended dosing interval (8 vs 2 weeks). Methods: The availability of eculizumab precluded the use of a concurrent placebo control in CHAMPION‐NMOSD; consequently, the placebo group of the eculizumab phase 3 trial PREVENT (n = 47) was used as an external comparator. Patients received weight‐based intravenous ravulizumab on day 1 and maintenance doses on day 15, then once every 8 weeks. The primary endpoint was time to first adjudicated on‐trial relapse. Results: The primary endpoint was met; no patients taking ravulizumab (n = 58) had an adjudicated relapse (during 84.0 patient‐years of treatment) versus 20 patients with adjudicated relapses in the placebo group of PREVENT (during 46.9 patient‐years; relapse risk reduction = 98.6%, 95% confidence interval = 89.7%–100.0%,p < 0.0001). Median (range) study period follow‐up time was 73.5 (11.0–117.7) weeks for ravulizumab. Most treatment‐emergent adverse events were mild/moderate; no deaths were reported. Two patients taking ravulizumab experienced meningococcal infections. Both recovered with no sequelae; one continued ravulizumab treatment. Interpretation: Ravulizumab significantly reduced relapse risk in patients with AQP4+ NMOSD, with a safety profile consistent with those of eculizumab and ravulizumab across all approved indications. ANN NEUROL 2023;93:1053–1068

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.26626

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 212

Metadata

Authors
Pittock, S. J., Barnett, M., Bennett, J. L., Berthele, A., de Sèze, J., Levy, M., Nakashima, I., Oreja‐Guevara, C., Palace, J., Paul, F., Pozzilli, C., Yountz, M., Allen, K., Mashhoon, Y., & Kim, H. J.
Venue
Annals of Neurology
Publisher
Wiley
Published
2023-04-05
Volume
93
Issue
6
Pages
1053-1068
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W4323036933
Cited by
212
References
6
FWCI
34.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder. https://app.cochat.ai/papers/10.1002/ana.26626
The paper
Pittock, S. J., Barnett, M., Bennett, J. L., Berthele, A., de Sèze, J., Levy, M., Nakashima, I., Oreja‐Guevara, C., Palace, J., Paul, F., Pozzilli, C., Yountz, M., Allen, K., Mashhoon, Y., & Kim, H. J. (2023). Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder. Annals of Neurology. https://doi.org/10.1002/ana.26626

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.